A startup pivot that touches the intended purpose almost always touches the device classification, because under Article 51 and Annex VIII of Regulation (EU) 2017/745, the class is a function of the intended purpose as defined in Article 2(12). When a founder changes what the device is for, they are changing the input that the classification rules read. The effect can be small — a rule re-check that confirms the same class — or large — a move from Class IIa to Class IIb, from Class I to out of the MDR entirely, or from a self-declaration path to a full Notified Body engagement. This post walks through the mechanics of a classification pivot, the types of pivots that change class, the distinction between re-assessment and continuation, the Notified Body implications, and how to plan a pivot with regulatory awareness from day one.

By Tibor Zechmeister and Felix Lenhard. Last updated 10 April 2026.

TL;DR

  • Classification under Annex VIII of Regulation (EU) 2017/745 is driven by the intended purpose as defined in Article 2(12). Change the intended purpose and the classification input changes with it.
  • Not every pivot changes the class. Technology pivots that keep the intended purpose stable usually do not. Commercial pivots that add a new indication, a new user, a new patient population, or a new clinical claim usually do.
  • The pivots that most often change class are: adding a diagnostic or therapeutic claim, extending the duration of use, adding an implantable or invasive component, pivoting software from informational to decision-support, and expanding patient populations into high-risk groups.
  • Re-assessment is required when the revised intended purpose activates a different Annex VIII rule or escalates within the same rule. Continuation is acceptable only when the intended purpose change is cosmetic and Annex VIII output is unchanged — and that must be documented.
  • Notified Body implications scale with the delta. A move within the same class may require a design change review under the existing certificate. A move to a higher class almost always means a new conformity assessment route and, for many startups, a new Notified Body engagement.
  • Plan the pivot on paper before you ship it. Write the revised intended purpose, re-run the Annex VIII classification sequence, identify the delta, and decide whether the commercial upside of the pivot justifies the regulatory work it triggers.

Why this matters — the Graz wellness pivot

A Graz-based startup had spent months building toward MDR certification. Notified Body shortlist in place, draft technical documentation outline, a clinical evaluation plan under construction. The project was organised around a specific assumed classification, and every downstream deliverable was scoped to that class.

Then the business reality shifted. Sales conversations were pointing the team toward a use case that did not need the full medical framing. The underlying hardware and software were the same. What changed was the commercial intent — who the customer was, what the customer was buying the product for, and what the company wanted to claim on the label and on the website.

We ran the Purpose Pass on the revised positioning. The medical claims came out. The clinical verbs from Article 2(1) — diagnosis, prevention, monitoring, prediction, prognosis, treatment, alleviation — were deliberately removed from the four sources Article 2(12) recognises: the label, the instructions for use, the promotional and sales materials, and the clinical evaluation. A revised intended purpose was drafted, one that genuinely described the product as a wellness device rather than a medical device.

The classification did not just change. It disappeared. Annex VIII did not apply because Article 2(1) no longer applied. The product entered the market under the relevant consumer product legislation on a timeline measured in weeks rather than quarters. The Notified Body engagement was avoided — not evaded, avoided, because the revised product genuinely was no longer a medical device under MDR.

That is the most dramatic kind of pivot this post covers. Most pivots are smaller, and most change the class without removing the MDR entirely. The mechanics are the same in every case: the intended purpose is the input, Annex VIII is the calculation, and the class is the output. Touch the input and the output moves.

How intended purpose drives classification

Classification under the MDR is not chosen, it is calculated. Article 51 of Regulation (EU) 2017/745 sets the classification framework. Annex VIII contains the twenty-two rules and the implementing principles. The input to those rules is the intended purpose.

Article 2(12) defines intended purpose as "the use for which a device is intended according to the data supplied by the manufacturer on the label, in the instructions for use, or in promotional or sales materials or statements, and as specified by the manufacturer in the clinical evaluation." That sentence is the entire hinge. The regulation reads the manufacturer's written statements in four places and uses them to run the classification rules.

Because the rules read the intended purpose — not the prototype, not the roadmap, not the investor pitch about a future version — the classification output is stable as long as the intended purpose is stable. When the intended purpose moves, the rules get a new input, and the output can move with it. A pivot that leaves the intended purpose untouched usually leaves the class untouched. A pivot that changes the intended purpose may or may not change the class, depending on whether the change activates a different rule or escalates within the same rule.

This is why the first step in any pivot-with-regulatory-awareness exercise is rewriting the intended purpose paragraph on paper, not rebuilding the product. The classification consequences can be read off the rewritten paragraph before any engineering change is made.

The pivot mechanics — what actually changes

A pivot, in startup language, is a deliberate change in the business model, the product, the customer, or the claim. In MDR language, the relevant question is narrower: does anything in the four Article 2(12) sources change as a result of the pivot?

Four mechanical questions decide whether a pivot touches classification.

Does the pivot change the label? A new medical claim on the physical label or packaging is the fastest path into a classification change.

Does the pivot change the instructions for use? New indications, new contraindications, new patient populations, new intended users, a new intended environment, or a new duration of use in the IFU are all classification inputs.

Does the pivot change the promotional or sales materials? Website copy, landing pages, investor decks, sales pitches, press releases, and app store descriptions are all Article 2(12) sources. A marketing pivot that adds a medical claim to the website is a classification pivot even if the IFU is untouched.

Does the pivot change the clinical evaluation? If the clinical evaluation now assesses a broader or different use than before, the intended purpose as specified in the clinical evaluation has moved.

If a pivot touches any of the four, the intended purpose has changed and the Annex VIII classification has to be re-run. If a pivot touches none of the four — for example, a back-end technology change that is invisible to the user and not reflected anywhere in the manufacturer's statements — the classification input has not moved and the existing class stands (though other regulatory obligations, such as change control under the QMS, may still apply).

Types of pivots that change the class

Across the pivots we see in startup coaching, certain patterns account for most of the classification movement.

Adding a diagnostic or therapeutic claim to an informational product. A wellness tracker that "helps you understand your sleep" and a device that "detects sleep apnea" are different devices under Annex VIII even if the hardware is identical. The diagnostic claim activates Rule 10 or Rule 11 in ways that the wellness claim does not.

Extending duration of use. Annex VIII defines transient (under 60 minutes of continuous intended use), short-term (60 minutes to 30 days), and long-term (over 30 days). A pivot from a session-based product to a continuously worn one can move a device across duration boundaries and with it across classes.

Adding invasiveness. A non-invasive product that adds a sensor requiring surgical implantation, or a body-orifice-invasive step, leaves the Rules 1-4 family and enters Rules 5-8. The class almost always moves up.

Pivoting software from informational to decision-support. Under Rule 11, software that provides information used for diagnostic or therapeutic decisions is Class IIa or higher, escalating to IIb for decisions that could cause serious deterioration of health and to III for decisions that could cause death or irreversible deterioration. A pivot from "view your data" to "the app will tell you what to do next" moves software across that line.

Expanding patient populations into high-risk groups. Adding paediatric use, use on the central nervous or central circulatory system, or use on critically ill patients can trigger rule escalation even when the core function is unchanged.

Adding a drug delivery or medicinal substance element. Special rules 14-22 include specific categories that escalate the class when a pivot introduces, for example, a medicinal substance with ancillary action or a drug-delivery function.

Not every pivot triggers these changes, but these are the patterns that most reliably do. A pivot conversation that does not explicitly check against this list is a pivot where the class has been changed by accident.

Re-assessment versus continuation

When a pivot does change the intended purpose, the next question is whether the existing classification — and the regulatory work built on top of it — can continue, or whether the classification must be re-assessed and potentially the whole conformity assessment redone.

Continuation is acceptable only when the revised intended purpose, run through Annex VIII, produces the same class, by the same rule, with no escalation within the rule. Even then, the change must be documented in the technical documentation, the classification rationale must be updated, and any ripple effects on clinical evaluation, risk management, and labelling must be worked through. Continuation is not "nothing to do." It is "the class output has not moved, so the conformity assessment route does not have to change."

Re-assessment is required when any of the following happen: a different Annex VIII rule now applies, the same rule now outputs a different class, an implementing rule now applies that did not before (for example, the accessory rule or the software-driving-hardware rule), a special rule from 14-22 now kicks in, or the Notified Body decides on review that the previous classification no longer holds.

Re-assessment does not automatically mean starting from scratch. It means running the Annex VIII sequence again, documenting the new class with the specific rule citation, identifying which parts of the existing technical documentation still apply and which need to be redone, and engaging the Notified Body on the delta. The amount of work scales with the delta, not with the word "pivot."

The mistake we see most often is founders treating a pivot as a pure business decision and then discovering, six months later, that the classification has silently changed and the existing conformity assessment no longer covers the device on the market. That discovery is usually made during a Notified Body surveillance audit, at which point the cost and delay multiply.

Notified Body implications

The Notified Body consequences of a pivot scale with the classification delta.

Within the same class, same rule, no escalation. The pivot is handled as a change under the QMS change control procedure. The technical documentation is updated. The Notified Body is notified according to the terms of the existing certificate. No new conformity assessment route. No new Notified Body.

Within the same class, different rule, or same rule with escalation within the class. The classification rationale is rewritten. The technical documentation is updated more extensively. The Notified Body reviews the change and decides whether it fits within the scope of the existing certificate or requires a significant change assessment. Clinical evaluation and risk management files will typically need updates.

Move to a higher class. A new conformity assessment route applies under Article 52. The existing certificate does not cover the new class. The manufacturer may need a new or expanded Notified Body engagement. For many startups, this is effectively a restart of the certification project for the pivoted product, even if the previous work on the predecessor device remains valid for that predecessor.

Move to a lower class. Rare but possible. Narrowing the intended purpose to exit a higher class is legitimate if the narrower purpose is honest. The previous conformity assessment still stands for the historical intended purpose; the narrower version may need a new classification rationale and, in some cases, a new conformity assessment under the lower-class route. The cost savings from the lower class usually materialise on the next certification cycle, not immediately.

Move out of the MDR entirely. The Graz pivot category. The existing conformity assessment is no longer relevant because the MDR no longer applies. The product enters the market under different legislation — wellness, general product safety, consumer electronics, cosmetics, depending on what it is. The documentation of why the MDR no longer applies is critical and must be defensible if a competent authority ever asks.

Every one of these scenarios is a legitimate outcome of a pivot done with regulatory awareness. None of them is a legitimate outcome of a pivot done without it, because the one where the founder did not realise the class moved is the one where the Notified Body finds out first.

How to plan a pivot with regulatory awareness

The discipline is simple to state and easy to skip. Before the pivot is committed to engineering, to marketing, or to investors, do the following on paper.

Write the revised intended purpose paragraph. Use the Article 2(12) structure — what the device is for, who uses it, on whom, for what condition (if any), in what environment, for how long. Make it internally consistent with what the revised label, IFU, marketing, and clinical evaluation will say.

Run the Annex VIII classification sequence against the revised paragraph. Identify the device type family, the applicable rule, the duration characterisation, and any special rules. Produce a new class with a specific rule citation. Compare to the existing class. Note the delta.

Cross-check against MDCG 2021-24 (October 2021) and the Borderline Manual v4 (September 2025). If the pivot moves the device close to a borderline — medical device vs. wellness, Class IIa vs. IIb, standalone software vs. accessory software — the guidance documents and the borderline manual are the first stop.

Identify the documentation impact. Which files need to be updated? Intended purpose statement, classification rationale, technical documentation index, clinical evaluation plan, risk management file, labelling, IFU, post-market surveillance plan. The list is usually longer than founders expect.

Identify the Notified Body impact. Does the existing certificate cover the revised device? Is a change notification sufficient? A significant change assessment? A new conformity assessment route? A new Notified Body engagement?

Decide whether the commercial upside justifies the regulatory work. Not every pivot survives this step, and that is a feature, not a bug. A pivot that looks attractive commercially but triggers a full re-certification cycle on top of the existing burn rate may not be a pivot the runway can absorb. A pivot that looks marginal commercially but costs nothing regulatorily may suddenly be worth doing.

Only after this six-step paper exercise is the pivot ready to be executed. The time cost of the exercise is usually one working session. The time cost of discovering the classification change after the pivot has already shipped is usually measured in quarters.

The Subtract to Ship angle

In the Subtract to Ship framework, the Purpose Pass is the first of four passes, and it runs before any engineering or regulatory work is scoped. A pivot is, functionally, a re-run of the Purpose Pass on a product that already exists. Everything the first Purpose Pass did for a new product — fix the intended purpose, narrow it to the honest minimum, align the four sources, identify the regulatory scope — has to happen again when the pivot lands.

The subtraction discipline is the same. The narrowest honest intended purpose, for the pivoted product, produces the smallest Annex VIII classification input, the smallest conformity assessment route, and the smallest regulatory workload consistent with the new business reality. A pivot executed without the Purpose Pass rerun almost always inflates the regulatory burden above what the new product actually needs, because the old intended purpose language survives in places it should not — in the IFU, on the website, in the clinical evaluation — and each of those residuals counts under Article 2(12).

The Subtract to Ship treatment of a pivot is: run the Purpose Pass again on the revised product, subtract the parts of the intended purpose that no longer apply, subtract the parts of the regulatory project that were scoped to the old intended purpose, add back only what the new intended purpose actually requires under Annex VIII and the downstream articles. What remains is the minimum regulatory work the pivoted product actually needs. Anything else is leftover work from the pre-pivot plan, and it is waste.

Reality Check — Where do you stand on your pivot?

  1. Have you written the revised intended purpose paragraph before starting engineering or marketing work on the pivot?
  2. Have you run the revised paragraph through the Annex VIII classification sequence and produced a new class with a specific rule citation?
  3. Have you identified which of the four Article 2(12) sources — label, IFU, promotional and sales materials, clinical evaluation — will change as part of the pivot?
  4. Do you know whether the pivot moves the device to a different Annex VIII rule, stays within the same rule with escalation, stays within the same rule with no escalation, or leaves the MDR scope entirely?
  5. Have you cross-checked the revised classification against MDCG 2021-24 and the Borderline Manual v4?
  6. Have you identified the delta in technical documentation, clinical evaluation, risk management, labelling, and post-market surveillance that the pivot triggers?
  7. Have you identified the Notified Body engagement delta — change notification, significant change assessment, new conformity assessment route, or new Notified Body — and priced it into the pivot decision?
  8. Does the commercial upside of the pivot justify the regulatory work it triggers within your current runway?

Frequently Asked Questions

Does every startup pivot change the MDR classification? No. A pivot that does not touch the four Article 2(12) sources — label, IFU, promotional and sales materials, clinical evaluation — does not change the intended purpose the regulation reads, and therefore does not change the Annex VIII classification input. Technology pivots that are invisible to the user and not reflected in any of the four sources typically leave the class untouched, though they may still require QMS change control.

What kinds of pivots most often change the class? Adding a diagnostic or therapeutic claim, extending duration of use across the transient / short-term / long-term boundaries in Annex VIII, adding invasiveness, pivoting software from informational to decision-support under Rule 11, expanding patient populations into high-risk groups, and adding a drug delivery or medicinal substance component. Each of these activates or escalates an Annex VIII rule.

If my pivot moves the device to a higher class, do I need a new Notified Body? Not always, but often. A move to a higher class triggers a different conformity assessment route under Article 52 and may exceed the scope of the existing Notified Body certificate. Whether a new Notified Body is required depends on the scope of the current certificate, the current Notified Body's designation, and the specific change. In many startup pivots, the practical answer is that a new or expanded engagement is required.

Can I pivot out of the MDR entirely by removing medical claims? Yes, if the revised product genuinely no longer meets the Article 2(1) definition of a medical device. This requires removing medical claims from all four Article 2(12) sources — not just the IFU — and documenting the reasoning. Borderline Manual v4 contains worked examples of products that sit on either side of this line depending on the manufacturer's stated purpose. The pivot must be honest; disguising a medical device as a wellness product to avoid the MDR is fraud under Article 7.

Does the existing certificate cover the device after a pivot? Only if the pivoted device falls within the scope of the certificate and the Notified Body accepts the change under the QMS change control procedure. If the pivot changes the class, changes the applicable Annex VIII rule, or changes the intended purpose materially, the existing certificate usually does not cover the pivoted device without a significant change assessment or a new conformity assessment.

How soon should I re-run the classification after a pivot? Before the pivot is executed, not after. The classification re-run is a paper exercise that costs one working session and tells you what the pivot will trigger regulatorily. Running it after the pivot has shipped means you discover the consequences after you have already committed to them. The correct sequence is: rewrite the intended purpose, re-run Annex VIII, decide whether the pivot is worth the regulatory delta, then execute.

What if the classification does not change but other regulatory obligations do? A pivot can leave the class unchanged while still triggering updates to the clinical evaluation, risk management file, labelling, IFU, post-market surveillance plan, and QMS change control records. "Class unchanged" is not the same as "no regulatory work." The delta exercise should cover all relevant files, not just the classification.

Sources

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, Article 2(1) (definition of medical device), Article 2(12) (definition of intended purpose), Article 51 (classification), Annex VIII (classification rules, including definitions, implementing rules, and Rules 1-22). Official Journal L 117, 5.5.2017.
  2. MDCG 2021-24 — Guidance on classification of medical devices, October 2021.
  3. Manual on borderline and classification for medical devices under Regulation (EU) 2017/745 and Regulation (EU) 2017/746, Version 4, September 2025 (Borderline and Classification Working Group of the MDCG).

This post is part of the Device Classification & Conformity Assessment series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. A pivot is a second chance to run the Purpose Pass. Take it on paper before you take it to engineering.